AtheroScreen provides rapid, decision-ready biological evidence for cardiovascular drug targets, grounded in real human diseased tissue and patient outcomes. We envision a future where cardiovascular drug programs are guided by direct evidence from human diseased tissue, rather than inferred late in development. 

Our mission is to support cardiovascular drug decisions by integrating molecular, histological and clinical outcome data from real human atherosclerotic plaques.

We deliver rapid, interpretable analyses that help R&D teams select targets, prioritize indications and identify relevant patient subgroups. Our core offering is a rapid evidence package informative for prioritization decisions, including target expression and cell-type context in human plaque, associations with lesion morphology and histology, links to circulating biomarkers, associations with clinical presentation and outcomes, early human-tissue liability signals, a concise, interpretative report.

Why AtheroScreen? Public resources are invaluable for exploration but lack disease-stage specificity, lesion-level histology and longitudinal outcome data. AtheroScreen provides curated, disease-relevant evidence directly linked to clinical endpoints. Animal models remain essential for mechanistic insights but only partially capture human plaque biology. AtheroScreen complements preclinical studies by anchoring hypotheses in the human biological context where drugs must ultimately act. All analyses are based on large, deeply phenotyped human plaque cohorts, comprising thousands of diseased vascular tissue samples with extensive histology, molecular profiling and long-term cardiovascular follow-up.

AtheroScreen was founded by cardiovascular scientists with long-standing expertise in human plaque biology, genetics, vascular multi-omics and clinical outcome integration. The team combines deep academic expertise with industry-facing project execution and collaborates closely with academic and clinical partners across Europe and the US.